For research and educational purposes only. Not medical advice.

CJC-1295 Reference

Educational, not medical advice reference for CJC-1295: GH Release, Longevity; regulatory status, evidence posture, source review, and schedule…

Reference summary

Published human data are primarily on the long-acting DAC-linked form, which increased GH and IGF-1 while preserving pulsatility in healthy men. No-DAC and DAC products are pharmacologically distinct, and long-term outcome data remain limited.

Regulatory and posture

Categories
GH Release, Longevity
Aliases
CJC-1295 acetate, CJC-1295 no DAC, CJC-1295 with DAC, GHRH analog, Mod GRF 1-29
Evidence posture
human - Human data are mainly small DAC-form endocrine studies, not broad long-term outcome trials.
Regulatory status
No FDA-approved CJC-1295 drug label. FDA lists CJC-1295 among bulk substances with safety-risk concerns for compounding.
Content review status
research reference

Selected public sources

Related tools